9vHPV Vaccine
Phase 3Active 1 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Papillomavirus Infections
Conditions
Papillomavirus Infections
Trial Timeline
Feb 18, 2022 → May 25, 2029
NCT ID
NCT05285826About 9vHPV Vaccine
9vHPV Vaccine is a phase 3 stage product being developed by Merck for Papillomavirus Infections. The current trial status is active. This product is registered under clinical trial identifier NCT05285826. Target conditions include Papillomavirus Infections.
What happened to similar drugs?
4 of 20 similar drugs in Papillomavirus Infections were approved
Approved (4) Terminated (0) Active (16)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05450705 | Phase 3 | Active |
| NCT05314023 | Phase 3 | Active |
| NCT05285826 | Phase 3 | Active |
| NCT04772534 | Phase 3 | Completed |
| NCT04708041 | Phase 3 | Active |
| NCT04199689 | Phase 3 | Active |
| NCT03546842 | Phase 3 | Completed |
| NCT01651949 | Phase 3 | Completed |
Competing Products
20 competing products in Papillomavirus Infections